These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7989764)

  • 21. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer.
    Rodolfo M; Zilocchi C; Accornero P; Cappetti B; Arioli I; Colombo MP
    J Immunol; 1999 Aug; 163(4):1923-8. PubMed ID: 10438927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
    Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
    Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Type 2 immune deviation has differential effects on alloreactive CD4+ and CD8+ T cells.
    Matesic D; Valujskikh A; Pearlman E; Higgins AW; Gilliam AC; Heeger PS
    J Immunol; 1998 Nov; 161(10):5236-44. PubMed ID: 9820495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus.
    Rosato A; Dalla Santa S; Zoso A; Giacomelli S; Milan G; Macino B; Tosello V; Dellabona P; Lollini PL; De Giovanni C; Zanovello P
    Cancer Res; 2003 May; 63(9):2158-63. PubMed ID: 12727834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Local release of interleukin-10 by transfected mouse adenocarcinoma cells exhibits pro- and anti-inflammatory activity and results in a delayed tumor rejection.
    Di Carlo E; Coletti A; Modesti A; Giovarelli M; Forni G; Musiani P
    Eur Cytokine Netw; 1998 Mar; 9(1):61-8. PubMed ID: 9613679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.
    Mortara L; Frangione V; Castellani P; De Lerma Barbaro A; Accolla RS
    Int Immunol; 2009 Jun; 21(6):655-65. PubMed ID: 19395374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
    Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The induction of in vivo proliferation of long-lived CD44hi CD8+ T cells after the injection of tumor cells expressing IFN-alpha1 into syngeneic mice.
    Belardelli F; Ferrantini M; Santini SM; Baccarini S; Proietti E; Colombo MP; Sprent J; Tough DF
    Cancer Res; 1998 Dec; 58(24):5795-802. PubMed ID: 9865738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells.
    Meazza R; Comes A; Orengo AM; Ferrini S; Accolla RS
    Eur J Immunol; 2003 May; 33(5):1183-92. PubMed ID: 12731043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells.
    Moeller M; Kershaw MH; Cameron R; Westwood JA; Trapani JA; Smyth MJ; Darcy PK
    Cancer Res; 2007 Dec; 67(23):11428-37. PubMed ID: 18056471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-9 promotes eosinophilic rejection of mouse heart allografts.
    Poulin LF; Richard M; Le Moine A; Kiss R; McKenzie AN; Goldman M; Renauld JC; Van Snick J; Braun MY
    Transplantation; 2003 Aug; 76(3):572-7. PubMed ID: 12923446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The immunologic function of 1B2+ double negative (CD4-CD8-) T cells in the 2C transgenic mouse.
    Margenthaler JA; Flye MW
    J Surg Res; 2005 Jun; 126(2):160-6. PubMed ID: 15919414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1.
    Carr-Brendel V; Markovic D; Ferrer K; Smith M; Taylor-Papadimitriou J; Cohen EP
    Cancer Res; 2000 May; 60(9):2435-43. PubMed ID: 10811121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors.
    Kawamura K; Bahar R; Natsume W; Sakiyama S; Tagawa M
    Cancer Gene Ther; 2002 Jan; 9(1):109-15. PubMed ID: 11916240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation.
    Cayeux S; Richter G; Noffz G; Dörken B; Blankenstein T
    J Immunol; 1997 Mar; 158(6):2834-41. PubMed ID: 9058819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
    Tatsumi T; Huang J; Gooding WE; Gambotto A; Robbins PD; Vujanovic NL; Alber SM; Watkins SC; Okada H; Storkus WJ
    Cancer Res; 2003 Oct; 63(19):6378-86. PubMed ID: 14559827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence.
    Luo Y; Zhou H; Mizutani M; Mizutani N; Liu C; Xiang R; Reisfeld RA
    Cancer Res; 2005 Apr; 65(8):3419-27. PubMed ID: 15833877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer.
    Reome JB; Hylind JC; Dutton RW; Dobrzanski MJ
    Clin Immunol; 2004 Apr; 111(1):69-81. PubMed ID: 15093554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
    Gri G; Chiodoni C; Gallo E; Stoppacciaro A; Liew FY; Colombo MP
    Cancer Res; 2002 Aug; 62(15):4390-7. PubMed ID: 12154045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.